News

Biocon Biologics secures market entry for Yesafili in US
Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon ...
High cholesterol three 'red flag' signs on your face you should never ignore
High cholesterol is a common health condition that doesn't usually produce any noticeable symptoms, but there are some ...
Abingdon Health: Meet the boss of the company going with the lateral flow
One day your life might depend on the development team at Abingdon Health, a Yorkshire-based lateral flow company which is ...
Ophthalmology Times4d
EMA application filed by Bayer to expand aflibercept 8 mg indication to include retinal vein occlusion
In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular ...
Pharmabiz4d
Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion
Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...
Optometry Advisor5d
COVID And The Eye: What We’ve Learned 5 Years Since The Start of The Pandemic
Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ...
Medical Dialogues5d
Bayer seeks EMA approval for Aflibercept for retinal vein occlusion treatment
Berlin: Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of aflibercept 8 mg (114.3 ...